1. Home
  2. AOD vs REPL Comparison

AOD vs REPL Comparison

Compare AOD & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Total Dynamic Dividend Fund of Beneficial Interest

AOD

abrdn Total Dynamic Dividend Fund of Beneficial Interest

HOLD

Current Price

$10.35

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$12.96

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AOD
REPL
Founded
N/A
2015
Country
United States
United States
Employees
N/A
465
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
AOD
REPL
Price
$10.35
$12.96
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$5.67
AVG Volume (30 Days)
389.7K
1.9M
Earning Date
01-01-0001
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.76
$1.50
52 Week High
$10.85
$16.33

Technical Indicators

Market Signals
Indicator
AOD
REPL
Relative Strength Index (RSI) N/A 49.68
Support Level N/A $12.40
Resistance Level N/A $16.02
Average True Range (ATR) 0.00 0.67
MACD 0.00 -0.20
Stochastic Oscillator 0.00 33.10

Price Performance

Historical Comparison
AOD
REPL

About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest

Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: